statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Zura Bio Commences Warrant Exchange Offer and Consent Solicitation

Zura Bio Limited (NASDAQ: ZURA) (Zura Bio or the Company), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that...

Zura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024

Zura Bio Limited (Nasdaq: ZURA) (Zura Bio), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today shared supportive data from a...

Zura Bio Forms Scientific Advisory Board with Prominent Specialists in Rheumatology, Dermatology, and Immunology

Zura Bio Limited (Nasdaq: ZURA) (Zura Bio), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced the formation of a...

Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024

Zura Bio Limited (Nasdaq: ZURA) (Zura Bio), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced it will present data...

Zura Bio Announces Participation in June Investor Conferences

Zura Bio Limited (Nasdaq: ZURA) (Zura Bio), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of...

Zura Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights

Zura Bio Limited (Nasdaq: ZURA) (Zura Bio), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported its...

Zura Bio Announces Oversubscribed $112.5 Million Private Placement

Zura Bio Limited (Nasdaq: ZURA) (Zura Bio), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that it...

Zura Bio Announces Robert Lisicki as CEO and Director

Zura Bio Limited (Nasdaq: ZURA) (Zura Bio) a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that Robert Lisicki...

Zura Bio price target lowered by $1 at Oppenheimer, here's why

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Zura Bio Ltd (ZURA) Reports Full Year 2023 Financial Results Amidst Leadership Transition

Zura Bio Ltd (ZURA) Aligns with EPS Projections, Net Loss Increases Significantly from Previous YearRelated Stocks: ZURA...

Zura Bio Ltd. is a clinical-stage biotechnology company that engages in the development of novel medicines for immune disorders. It focuses on the development of ZB-168, a treatment for Alopecia Areata and other inflammatory diseases. The company was founded by Someit Sidhu on January 18, 2022 and is headquartered in Henderson, NV.

Volume	259,107.00
52-Wk High	$7.63
52-Wk Low	$2.00

ZURA Zura Bio Ltd - Ordinary Shares - Class A

About

Feed

News

Sentiment

Fundamentals